Pith. sign in

REVIEW 2 major objections 2 minor 12 references

Reviewed by Pith at T0; open to challenge.

T0 means a machine referee read the full paper against a public rubric. The mark states how deep the mechanical check went, never who wrote it. the ladder, T0–T4 →

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

T0 review · grok-4.3

Residual false positives in prostate MRI detection match the contrast profile of true cancers in raw T2, ADC, and high-b-value images across five architectures.

2026-06-30 04:24 UTC pith:DUNK2FA2

load-bearing objection The paper replicates contrast-matching of false positives to true lesions across five architectures and shows a small refinement head can lift specificity on some folds, but the data-level interpretation lacks histology on the FP regions themselves. the 2 major comments →

arxiv 2606.29977 v1 pith:DUNK2FA2 submitted 2026-06-29 eess.IV cs.CVcs.LG

A multi-architecture study of specificity refinement and false-positive mechanism analysis in prostate MRI

Yongbo Shu , Kewen Chen , Yifeng Yuan , Zirui Xin , Luo Lei , Yang Yang , Xi Chen , Aijing Luo This is my paper
classification eess.IV cs.CVcs.LG
keywords prostate MRIfalse positivesspecificitycontrast matchingmulti-architecturePI-CAIrefinement headADC imaging
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The study examines why false-positive detections remain in AI models for prostate cancer on MRI even after training. It measures contrast ratios of false-positive regions against surrounding tissue and compares them to confirmed cancers and benign areas. The ratios align more closely with cancers than with benign tissue, and this pattern appears consistently no matter which detection backbone is used. A small post-processing head can raise specificity on some data splits without losing sensitivity, but the gain varies by fold and does not appear on external data.

Core claim

False-positive regions exhibit T2-weighted, apparent-diffusion-coefficient, and high-b-value contrast ratios versus peri-lesional rings that are statistically closer to ground-truth lesions than to contralateral benign regions, reproducing in 35 of 35 architecture comparisons and 105 of 105 modality-perturbation tests; a lightweight refinement head trained on a frozen backbone raises case-level specificity from 0.469 to 0.549 on one PI-CAI fold at preserved sensitivity while showing fold-conditional behavior overall.

What carries the argument

Contrast-ratio comparison of false-positive regions against peri-lesional rings in T2-weighted, ADC, and high-b-value images, together with the 89,216-parameter refinement head attached to frozen detection backbones.

Load-bearing premise

That measured contrast ratios in T2-weighted, ADC, and high-b-value images versus peri-lesional rings can separate data-level imaging similarity from model artifact without histological confirmation of the false-positive regions themselves.

What would settle it

Histological sampling of the false-positive regions to determine whether they contain cancer cells or other tissue that would produce the observed contrast match.

Watch this falsifier — get emailed when new claim-graph text bears on it.

If this is right

  • Residual false positives arise from shared raw imaging features rather than architecture-specific mistakes.
  • The same contrast-matching pattern appears in every tested backbone and on external Prostate158 data.
  • Post-hoc refinement improves case-level specificity by 17 percent on in-domain folds at fixed sensitivity.
  • Specificity gains from refinement are fold-dependent and do not reach significance on external data.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • Detection pipelines may benefit from explicit penalties on peri-lesional contrast similarity during training.
  • The data-level nature of the errors implies that architectural scaling alone is unlikely to eliminate them.
  • Fold-conditional refinement suggests that adaptive or ensemble post-processing could stabilize gains across validation splits.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit.

Referee Report

2 major / 2 minor

Summary. The manuscript reports an observational study on residual false positives (FPs) in prostate MRI lesion detection using 5-fold cross-validation on PI-CAI and external validation on Prostate158 (n=158). It claims that FP regions exhibit T2-weighted, ADC, and high-b-value contrast ratios versus peri-lesional rings that match ground-truth lesions more closely than benign tissue (Cohen's d 1.10; FP/benign evidence ratio 2.38x), with this pattern replicating across five architectures (35/35) and modality-perturbation scenarios (105/105). A lightweight 89,216-parameter post-hoc refinement head improves case-level specificity on PI-CAI fold-0 (+17.2% at preserved sensitivity) but shows fold-conditional behavior overall; both models saturate on the external set.

Significance. If the contrast-matching result holds after addressing the inference gap, the work would indicate that residual FPs in prostate MRI are driven by data-level imaging properties rather than architecture-specific artifacts, with implications for dataset annotation quality and model development. Strengths include the consistent cross-architecture replication, external held-out validation, and the low-parameter refinement approach that could be practically useful in-domain.

major comments (2)
  1. [Results (contrast comparisons)] Results (contrast comparisons paragraph): The central claim that residual FPs share raw imaging features with cancer 'rather than histologically confirmed mimicry' and thus represent a data-level property (not model artifacts) rests on T2/ADC/high-b contrast ratios versus peri-lesional rings. Without histological sampling or biopsy correlation on the FP regions themselves, the measurement cannot distinguish data-level similarity from undetected occult cancers missed by PI-CAI annotations or non-mimic tissue with coincident contrast; this inference is load-bearing for the data-level conclusion and the cross-architecture interpretation.
  2. [Results (refinement performance)] Results (refinement performance): Specificity gains are reported as fold-conditional (9/15 observations positive; range -22% to +28%), yet the abstract and conclusion still frame the refinement head as adding 'practical specificity in-domain.' This variability requires explicit quantification of when gains occur (e.g., relation to fold-specific FP distributions) to support the practical-utility claim.
minor comments (2)
  1. [Abstract/Methods] Abstract and Methods: The replication counts (35/35, 105/105) and Cohen's d values are presented without accompanying statistical testing details or confidence intervals for the contrast ratios; adding these would clarify the strength of the replication evidence.
  2. [Methods] Methods: The definition of peri-lesional rings (size, exclusion of other lesions) and any data exclusion rules for FP regions are not fully specified, which affects reproducibility of the contrast ratio analysis.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for the detailed and constructive comments on our manuscript. Below we provide point-by-point responses to the major comments, indicating where revisions will be made to address the concerns while preserving the core observational findings.

read point-by-point responses

  1. Referee: Results (contrast comparisons paragraph): The central claim that residual FPs share raw imaging features with cancer 'rather than histologically confirmed mimicry' and thus represent a data-level property (not model artifacts) rests on T2/ADC/high-b contrast ratios versus peri-lesional rings. Without histological sampling or biopsy correlation on the FP regions themselves, the measurement cannot distinguish data-level similarity from undetected occult cancers missed by PI-CAI annotations or non-mimic tissue with coincident contrast; this inference is load-bearing for the data-level conclusion and the cross-architecture interpretation.

    Authors: We agree that without direct histological sampling of the FP regions, the contrast-ratio measurements cannot exclude the possibility of occult cancers missed by the PI-CAI annotations or non-mimic tissue exhibiting similar contrast by coincidence. The manuscript's primary observation remains the quantitative similarity in T2/ADC/high-b contrast ratios (Cohen's d 1.10; FP/benign evidence ratio 2.38x) that replicates across all five architectures (35/35) and all modality-perturbation scenarios (105/105). This replication supports the interpretation that the phenomenon is driven by data-level imaging properties rather than architecture-specific model artifacts. We will revise the abstract, results, and conclusion to remove the phrasing 'rather than histologically confirmed mimicry' and instead describe the finding strictly as an observational contrast-matching result, while retaining the cross-architecture replication evidence. revision: partial

  2. Referee: Results (refinement performance): Specificity gains are reported as fold-conditional (9/15 observations positive; range -22% to +28%), yet the abstract and conclusion still frame the refinement head as adding 'practical specificity in-domain.' This variability requires explicit quantification of when gains occur (e.g., relation to fold-specific FP distributions) to support the practical-utility claim.

    Authors: We accept that the fold-conditional nature of the specificity gains (already quantified as 9/15 positive observations with range -22% to +28%) requires further contextualization to support claims of practical utility. In the revised manuscript we will add an analysis that correlates per-fold specificity changes with fold-specific FP prevalence, contrast-ratio distributions, and lesion characteristics to identify the conditions under which the 89,216-parameter refinement head improves performance. revision: yes

Circularity Check

0 steps flagged

No significant circularity; empirical observational study

full rationale

The paper is an empirical study reporting contrast-ratio measurements, replication counts (35/35, 105/105), and performance metrics on 5-fold CV plus external held-out data. No equations, fitted parameters renamed as predictions, self-definitional constructs, or load-bearing self-citations appear in the provided text. Central claims rest on direct observational comparisons rather than any derivation that reduces to its own inputs by construction. This matches the default expectation for non-circular empirical work.

Axiom & Free-Parameter Ledger

1 free parameters · 2 axioms · 0 invented entities

The central claim rests on standard retrospective medical imaging assumptions and the validity of contrast ratio comparisons as evidence for data-level properties rather than model artifacts.

free parameters (1)
  • refinement head parameter count
    The lightweight refinement head is specified as having 89,216 parameters; this size is chosen to keep the module small.
axioms (2)
  • domain assumption Retrospective use of PI-CAI 5-fold cross-validation and Prostate158 external set is appropriate for evaluating the claims
    The study design relies on these datasets and validation scheme without prospective confirmation.
  • domain assumption Contrast ratios versus peri-lesional rings serve as a valid proxy for imaging-feature similarity to cancer
    This measurement underpins the data-level versus model-artifact distinction.

pith-pipeline@v0.9.1-grok · 5879 in / 1522 out tokens · 74771 ms · 2026-06-30T04:24:29.831840+00:00 · methodology

0 comments
read the original abstract

Objectives: To characterize residual false positives in prostate MRI detection, and to evaluate a lightweight post-hoc refinement head for case-level specificity. Materials and Methods: This retrospective study used PI-CAI (5-fold cross-validation) and Prostate158 (n=158; external). A context-aware evidence head and an 89,216-parameter refinement head were trained on a frozen detection backbone; the evidence head was also trained on four further backbones (bare nnU-Net, bare U-Net, bare Mamba, MIGF-Mamba). For each false-positive region, T2-weighted, apparent-diffusion-coefficient, and high-b-value contrast ratios versus peri-lesional rings were compared against ground-truth lesions and contralateral benign regions. Results: False positives were closer to true cancers than to benign tissue in evidence and raw T2-weighted and apparent-diffusion-coefficient contrast, reproducing 35/35 across five architectures (Cohen's d 1.10; FP/benign evidence ratio 2.38x) and 105/105 across modality-perturbation scenarios. On PI-CAI fold-0, refinement raised case-level specificity from 0.469 to 0.549 (+17.2%) at preserved sensitivity (0.943); 5-fold cross-validation showed fold-conditional behavior (9/15 observations positive; range -22% to +28%). On Prostate158, both models saturated (McNemar pooled p=0.69), while the false-positive contrast-matching finding replicated. Conclusion: Residual false positives are contrast-matched to cancer (sharing raw imaging features rather than histologically confirmed mimicry), reproducing across five architectures -- a data-level imaging property, not model-specific artifacts; post-hoc refinement adds practical specificity in-domain but is fold-conditional.

Figures

Figures reproduced from arXiv: 2606.29977 by Aijing Luo, Kewen Chen, Luo Lei, Xi Chen, Yang Yang, Yifeng Yuan, Yongbo Shu, Zirui Xin.

Figure 1
Figure 1. Figure 1: Study flowchart. PI-CAI Public Training and Development Cohort (n = 1500 studies) was partitioned using the official 5-fold cross-validation split; fold 0 (1200 training, 300 validation studies) provided the primary evaluation set. All 158 Prostate158 studies served as the external replication cohort. The refinement head was trained on PI-CAI fold-0 training studies only; no Prostate158 data were used for … view at source ↗
Figure 2
Figure 2. Figure 2: Case-level specificity versus case-level sensitivity on PI-CAI fold-0 validation for the frozen backbone (“bare A2”) and the refined model (“P2a ms v2”), 5 seeds. Each point is a seed; the refined model cluster sits at higher specificity at equal mean sensitivity. Points are annotated with seed identifier for transparency. 11 [PITH_FULL_IMAGE:figures/full_fig_p011_2.png] view at source ↗
Figure 3
Figure 3. Figure 3: Evidence prediction on PI-CAI fold-0 validation. (a) Overall mean absolute error (MAE) for the three evidence-prediction variants (mask-only, image-aware, context-aware) across 5 seeds; seed-level paired points. (b) Per-target coefficient of determination (R2 ) heatmap for the six continuous contrast-ratio targets; darker indicates higher R2 . 12 [PITH_FULL_IMAGE:figures/full_fig_p012_3.png] view at source ↗
Figure 4
Figure 4. Figure 4: Raw false-positive evidence analysis on PI-CAI. Distribution of per-case contrast ratios (region mean minus peri-ring mean, normalized by absolute peri-ring mean) in (a) T2-weighted and (b) apparent-diffusion-coefficient channels, for ground-truth lesions, backbone false-positive regions, and contralateral benign regions of interest. False-positive contrast distributions sit on the same side as ground-trut… view at source ↗
Figure 5
Figure 5. Figure 5: Cross-center replication of the false-positive contrast-matching finding. Side-by-side comparison of apparent-diffusion-coefficient contrast distributions for ground-truth lesions, false positives, and benign regions on PI-CAI and Prostate158. The directional ordering (“false positive closer to cancer than to benign”) is preserved in both cohorts across all 5 seeds. 14 [PITH_FULL_IMAGE:figures/full_fig_p0… view at source ↗
Figure 6
Figure 6. Figure 6: (a) Matched-sensitivity case-level specificity on PI-CAI and Prostate158 for the threshold￾sweep baseline versus the P2a refinement head (5-seed mean +/- sample standard deviation); the +3.8-percentage-point advantage on PI-CAI is annotated. (b) Per-tier false-positive suppression rate by cosine-similarity tertile (high, mid, low) of the backbone’s dec2 feature vector to the true-cancer centroid, on both c… view at source ↗

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

12 extracted references · 7 canonical work pages · 1 internal anchor

  1. [1]

    Lancet Oncol 25:879–887

    Saha A, Bosma JS, Twilt JJ, et al (2024) Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): An international, paired, non-inferiority, confirmatory study. Lancet Oncol 25:879–887. https://doi.org/10.1016/S1470-2045(24)00220-1

    work page doi:10.1016/s1470-2045(24)00220-1 2024

  2. [2]

    European Urology 64:876–892

    Loeb S, Vellekoop A, Ahmed HU, et al (2013) Systematic review of complications of prostate biopsy. European Urology 64:876–892. https://doi.org/10.1016/j.eururo.2013.05.049

    work page doi:10.1016/j.eururo.2013.05.049 2013

  3. [3]

    Urol Clin North Am 41:299–313

    Bjurlin MA, Wysock JS, Taneja SS (2014) Optimization of prostate biopsy: Review of technique and complications. Urol Clin North Am 41:299–313. https://doi.org/10.1016/j.ucl. 2014.01.011

    work page doi:10.1016/j.ucl 2014

  4. [4]

    Shu Y et al (2026) Backbone-conditional behavior of modality gating in multi-modal prostate MRI segmentation: A 5-fold cross-validation and gate mechanism analysis. arXiv. https: //doi.org/10.48550/arXiv.2604.10702

    work page internal anchor Pith review Pith/arXiv arXiv doi:10.48550/arxiv.2604.10702 2026

  5. [5]

    Comput Biol Med 148:105817

    Adams LC, Makowski MR, Engel G, et al (2022) Prostate158 – an expert-annotated 3T MRI dataset and algorithm for prostate cancer detection. Comput Biol Med 148:105817. https://doi.org/10.1016/j.compbiomed.2022.105817 8

    work page doi:10.1016/j.compbiomed.2022.105817 2022

  6. [6]

    https://github.com/DIAGNijmegen/picai_eval

    DIAG Nijmegen (2022) Picai_eval: Evaluation utilities for 3D detection and diagnosis in medical imaging. https://github.com/DIAGNijmegen/picai_eval. Accessed 30 Mar 2026

    2022

  7. [7]

    Radiology: Artificial Intelligence 6:e240300

    Mongan J, Moy L, Kahn CE (2024) Checklist for artificial intelligence in medical imaging (CLAIM): 2024 update. Radiology: Artificial Intelligence 6:e240300. https://doi.org/10.114 8/ryai.240300

    2024

  8. [8]

    Inf Fusion 113:102648

    Huang L, Ruan S, Decazes P, Denœux T (2025) Deep evidential fusion with uncertainty quantification and reliability learning for multimodal medical image segmentation. Inf Fusion 113:102648. https://doi.org/10.1016/j.inffus.2024.102648

    work page doi:10.1016/j.inffus.2024.102648 2025

  9. [9]

    In: Proceedings of the IEEE/CVF conference on computer vision and pattern recognition (CVPR)

    Wang H, Chen Y, Ma C, et al (2023) Multi-modal learning with missing modality via shared-specific feature modelling. In: Proceedings of the IEEE/CVF conference on computer vision and pattern recognition (CVPR). pp 15878–15887

    2023

  10. [10]

    In: Wang L, Dou Q, Fletcher PT, et al (eds) Medical image computing and computer assisted intervention – MICCAI

    Zhang Y, He N, Yang J, et al (2022) mmFormer: Multimodal medical transformer for incomplete multimodal learning of brain tumor segmentation. In: Wang L, Dou Q, Fletcher PT, et al (eds) Medical image computing and computer assisted intervention – MICCAI

    2022

  11. [11]

    Springer Nature Switzerland, Cham, pp 107–117

  12. [12]

    bare A2”) and the refined model (“P2a ms v2

    Havaei M, Guizard N, Chapados N, Bengio Y (2016) HeMIS: Hetero-modal image segmen- tation. In: Medical image computing and computer assisted intervention – MICCAI 2016. Springer International Publishing, Cham, pp 469–477 9 Figures Column A — PI-CAI (primary cohort) Column B — Prostate158 (external cohort) PI-CAI (n = 1500) Fold-0 split: 1200 train / 300 v...

    work page arXiv 2016